Approved in France for the type 2 diabetes (under the name Ozempic) and to treat obesity (under the name Wegovy), the GLP-1 molecule continues to be talked about. The list of pathologies in which it seems to show a positive effect is growing longer by the month: heart disease, kidney disease, Parkinson's, Alzheimer's, depression or addiction are all areas in which this drug raises hope.
So much so that it becomes difficult to see very clearly between the proven effects and those which remain supposed. The review Scientists are able to explain the origins of science takes stock of what we know and, above all, what we still don't know about this very mysterious molecule.
English 
French